Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
atypical antipsychotics
Pharma
BMS' schizophrenia drug stumbles in blow to blockbuster plan
Cobenfy, a key component in BMS’ plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback in schizophrenia.
Angus Liu
Apr 23, 2025 10:35am
Intra-Cellular's unstoppable Caplyta nails another trial
Nov 5, 2024 10:15am
Intra-Cellular moves closer to Caplyta depression expansion
Apr 16, 2024 2:27pm
Rovi wins FDA nod to make Moderna's COVID shot at Spanish plant
Feb 28, 2024 11:22am
Teva taps Royalty to bankroll long-acting schizophrenia drug
Nov 13, 2023 11:40am
Takeda, AstraZeneca, Astellas and more—Fierce Pharma Asia
May 19, 2023 9:25am
